Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 12/20 | 0.66 |
| ▸ | RAB9A | P51151 | 12/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.54 |
| ▸ | PLAU | P00749 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5713502 | 0.80 | NPC1 (0.72) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3405794 | 0.78 | NPC1 (0.53) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL8900971 | 0.77 | KDM4E (0.50) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL3050086 | 0.73 | MEN1 (0.70) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL8900141 | 0.72 | KDM4E (0.44) | NPC1RAB9ASMN1; SMN2KDM4EMAPT | |
| SCHEMBL5214200 | 0.72 | CSNK2A2 (0.71) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| N-(Phenylcarbamothioyl)Benzamide SCHEMBL2341910 | 0.72 | EPHX1 (1.00) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL5818769 | 0.71 | NPC1 (1.00) | NPC1RAB9AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL8901234 | 0.71 | CYP3A4 (0.50) | NPC1RAB9AKDM4EHPGDMAPT | |
| SCHEMBL8615770 | 0.71 | EPHX1 (0.68) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188284-B2 | 2-aminoquinolines | HOFFMAN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20090227583-A1 | 2-AMINOQUINOLINES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227583-A1 | 2-AMINOQUINOLINES | HTR5A, HTR2C, HTR2B | NPC1 2445/4885RAB9A 177/4885ALDH1A1 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.